Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Current Assets
All assets expected to be converted to cash or used up within one year.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 150.1% from a year ago
Total current assets stood at $137.74M at the end of Q1 FY2026, up 150.1% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at +120.1% a year.
Context
- Total current assets amounted to 99.8% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +150.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 140.46M USD
- Year-over-year change
- +133.0%
- 4-year CAGR
- +61.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.46M | +133.0% |
| FY2024 | 2024-12-31 | 60.29M | +722.2% |
| FY2023 | 2023-12-31 | 7.33M | -44.3% |
| FY2022 | 2022-12-31 | 13.17M | -35.8% |
| FY2021 | 2021-12-31 | 20.52M | — |
Total Current Assets vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +150.1% is the highest of 11, against a peer median of +4.6%.
- Total current assets amounts to 99.8% of total assets for MNPR, versus a peer median of 88.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $619.14M USD | -27.7% | +19.4% | 94.9% | |
| Sep 2026 | $532.4M USD | +82.5% | -24.6% | 45.3% | |
| Jun 2026 | $523.21M USD | +2.0% | -3.9% | 72.2% | |
| Sep 2026 | $477.8M USD | +70.7% | +207.8% | 94.5% | |
| Mar 2026 | $276.77M USD | +7.3% | -11.0% | 94.9% | |
| Mar 2026 | $195.69M USD | +57.6% | +2.5% | 95.4% | |
| Mar 2026 | $182.52M USD | +0.2% | -0.3% | 83.8% | |
| Mar 2026 | $145.56M USD | +42.0% | -42.8% | 81.6% | |
| Mar 2026 | $137.74M USD | +150.1% | +120.1% | 99.8% | |
| Dec 2025 | €46.69M EUR | -45.5% | -30.6% | 74.5% | |
| Jun 2026 | $37.74M USD | -38.2% | -23.6% | 94.0% | |
| Peer median (excluding MNPR) | — | +4.6% | -7.5% | 88.9% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.